TN2013000322A1 - Pharmaceutical compositions comprising human antibodies to pcsk9 - Google Patents
Pharmaceutical compositions comprising human antibodies to pcsk9Info
- Publication number
- TN2013000322A1 TN2013000322A1 TNP2013000322A TN2013000322A TN2013000322A1 TN 2013000322 A1 TN2013000322 A1 TN 2013000322A1 TN P2013000322 A TNP2013000322 A TN P2013000322A TN 2013000322 A TN2013000322 A TN 2013000322A TN 2013000322 A1 TN2013000322 A1 TN 2013000322A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pcsk9
- antigen
- present
- antibodies
- binding fragments
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 8
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract 8
- 239000012634 fragment Substances 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000005022 packaging material Substances 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306450 | 2011-11-08 | ||
| PCT/EP2012/051321 WO2012101253A1 (en) | 2011-01-28 | 2012-01-27 | Pharmaceutical compositions comprising human antibodies to pcsk9 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000322A1 true TN2013000322A1 (en) | 2015-01-20 |
Family
ID=54337507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000322A TN2013000322A1 (en) | 2011-11-08 | 2013-07-26 | Pharmaceutical compositions comprising human antibodies to pcsk9 |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TN2013000322A1 (en) |
-
2013
- 2013-07-26 TN TNP2013000322A patent/TN2013000322A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500018A1 (en) | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects | |
| AR124482A2 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING HUMAN ANTIBODIES AGAINST PCSK9 | |
| BR112014005799A2 (en) | antibodies to pcsk9, their uses, and pharmaceutical composition | |
| MY170089A (en) | Methods for reducing lipoproten(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) | |
| MX2016006226A (en) | Dosing regimens for use with pcsk9 inhibitors. | |
| MX2014001372A (en) | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer. | |
| EA201490378A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β | |
| NZ606988A (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
| NZ702315A (en) | Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors | |
| EA201490653A1 (en) | DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, METHOD FOR THEIR PRODUCTION CONTAINING THEIR PHARMACEUTICAL PREPARATIONS | |
| EA201400002A1 (en) | METHODS TO TREAT DISEASES OF THE RETAIL | |
| NZ606969A (en) | A method of treating alzheimer’s disease | |
| TN2013000322A1 (en) | Pharmaceutical compositions comprising human antibodies to pcsk9 | |
| MX2013002503A (en) | Combination of hdac inhibitors with thrombocytopenia drugs. | |
| UA56025U (en) | Method for determination of illegal drugs and drastic medicinal agents in human biological material | |
| EA201201226A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) |